CR Double-Crane Q1 2026 Revenue Down 8.84%, Net Profit Declines 4.08%; Majority-Owned by CR Pharma

Bulletin Express04-24

China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the three months ended 31 March 2026.

Revenue fell 8.84% year on year to RMB 2.81 billion, while net profit slipped 4.08% to RMB 0.50 billion.

Operating cash generation strengthened: net cash inflow rose 141.90% to RMB 0.66 billion. However, end-period cash and cash equivalents contracted 17.50% to RMB 2.57 billion.

Total assets expanded 5.87% versus 31 December 2025 to RMB 18.01 billion. Total liabilities increased 11.00% to RMB 5.00 billion, lifting the debt ratio to 27.79%. Owner’s equity improved 4.02% to RMB 13.00 billion.

The figures are prepared under PRC GAAP and remain unaudited; they represent CR Double-Crane only and do not reflect the consolidated position of CR Pharma. Shareholders should exercise caution when interpreting these standalone results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106465831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106465831","market":"hk","top_or_hot":-1,"title":"CR Double-Crane Q1 2026 Revenue Down 8.84%, Net Profit Declines 4.08%; Majority-Owned by CR Pharma","media":"Bulletin Express","content":"<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the three months ended 31 March 2026.</p>\n<p>Revenue fell 8.84% year on year to RMB 2.81 billion, while net profit slipped 4.08% to RMB 0.50 billion.</p>\n<p>Operating cash generation strengthened: net cash inflow rose 141.90% to RMB 0.66 billion. However, end-period cash and cash equivalents contracted 17.50% to RMB 2.57 billion.</p>\n<p>Total assets expanded 5.87% versus 31 December 2025 to RMB 18.01 billion. Total liabilities increased 11.00% to RMB 5.00 billion, lifting the debt ratio to 27.79%. Owner’s equity improved 4.02% to RMB 13.00 billion.</p>\n<p>The figures are prepared under PRC GAAP and remain unaudited; they represent CR Double-Crane only and do not reflect the consolidated position of CR Pharma. Shareholders should exercise caution when interpreting these standalone results.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Double-Crane Q1 2026 Revenue Down 8.84%, Net Profit Declines 4.08%; Majority-Owned by CR Pharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Double-Crane Q1 2026 Revenue Down 8.84%, Net Profit Declines 4.08%; Majority-Owned by CR Pharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-24 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the three months ended 31 March 2026.</p>\n<p>Revenue fell 8.84% year on year to RMB 2.81 billion, while net profit slipped 4.08% to RMB 0.50 billion.</p>\n<p>Operating cash generation strengthened: net cash inflow rose 141.90% to RMB 0.66 billion. However, end-period cash and cash equivalents contracted 17.50% to RMB 2.57 billion.</p>\n<p>Total assets expanded 5.87% versus 31 December 2025 to RMB 18.01 billion. Total liabilities increased 11.00% to RMB 5.00 billion, lifting the debt ratio to 27.79%. Owner’s equity improved 4.02% to RMB 13.00 billion.</p>\n<p>The figures are prepared under PRC GAAP and remain unaudited; they represent CR Double-Crane only and do not reflect the consolidated position of CR Pharma. Shareholders should exercise caution when interpreting these standalone results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1106465831","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106465831","pubTimestamp":1777023948,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润双鹤2026年第一季度营收下降8.84%，净利润下降4.08%；由华润医药拥有多数股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane), a 60.25%-owned subsidiary of China Resources Pharmaceutical Group Limited (CR Pharma), released unaudited results for the three months ended 31 March 2026.\nRevenue fell 8.84% year on year to RMB 2.81 billion, while net profit slipped 4.08% to RMB 0.50 billion.\nOperating cash generation strengthened: net cash inflow rose 141.90% to RMB 0.66 billion. However, end-period cash and cash equivalents contracted 17.50% to RMB 2.57 billion.\nTotal assets expanded 5.87% versus 31 December 2025 to RMB 18.01 billion. Total liabilities increased 11.00% to RMB 5.00 billion, lifting the debt ratio to 27.79%. Owner’s equity improved 4.02% to RMB 13.00 billion.\nThe figures are prepared under PRC GAAP and remain unaudited; they represent CR Double-Crane only and do not reflect the consolidated position of CR Pharma. Shareholders should exercise caution when interpreting these standalone results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106465831","isCrawlerRequest":true}